Effect of Prophylatic Use of Enoxaparin in Women Undergoing in Vitro Fertilization Treatment

ABC Foundation (FUABC)

Status: Completed

Conditions: Fertilization in Vitro; Thrombophilia; Infertility, Female

Treatments: Drug: Enoxaparin

Study type: Observational

Funder types: Other

Identifiers

NCT05225155

41006620.0.0000.0082

Details and patient eligibility

About

Retrospective study designed to evaluate outcomes in patients undergoing assisted reproduction. Some of them had thrombophilia, and part of them was treated with enoxaparin, started on the day of embryo transfer, and the other part not. Women without thrombophilia formed the control group.

Full description

A retrospective study was performed to evaluate the results in 104 patients undergoing to assisted reproduction. Women without thrombophilia were included as controls (n=20), while women with thrombophilia were either treated with 40 mg daily of enoxaparin (treated group, n=54), initiated on the day of embryo transfer, and continued to the week 36 of gestation, or did not receive this medication (untreated group, n= 30).

Enrollment: 104 patients

Sex: Female

Volunteers: No Healthy Volunteers

Inclusion criteria

• Women with female infertility or unexplained infertility
• Normal sperm analysis

Exclusion criteria

• Women who did not agree with in vitro fertilization techniques

Trial design

104 participants in 3 patient groups

Control

Description:

Women without thrombophilia, submitted to in vitro fertilization techniques

Untreated Thrombophilia

Description:

Women with laboratorial thrombophilia, submitted to in vitro fertilization techniques, without treatment with enoxaparin

Treated Thrombophilia

Description:

Women with laboratorial thrombophilia, submitted to in vitro fertilization techniques, and treated with enoxaparin

Treatment:

Drug: Enoxaparin